News from the FDA/CDC
News from the FDA/CDC
Global measles deaths increased by 43% in 2022
The report also notes an increase in the number of countries experiencing significant measles outbreaks. There were 37 such countries in 2022,...
News
FDA warns of potentially lethal reaction to seizure meds
Diagnosis is often difficult because early signs and symptoms, such as fever and swollen lymph nodes, may be present without evidence of a rash....
News from the FDA/CDC
New CDC advisory once again flags BA.2.86 COVID variant
The variant accounted for nearly 9% of cases during the 2-week period ending Nov. 25, up from 3% during the previous 2 weeks.
News from the FDA/CDC
New at-home test approved for chlamydia and gonorrhea
“This authorization marks an important public health milestone, giving patients more information about their health from the privacy of their own...
News from the FDA/CDC
FDA approves tirzepatide for treating obesity
Zepbound should go to market in the United States by year’s end, with an anticipated monthly list price of $1,060.
News
Test all perinatally exposed infants for HCV: CDC
The CDC noted that rates of HCV infections during pregnancy are on the rise.
News from the FDA/CDC
FDA OKs new treatment for erosive esophagitis
Vonoprazan provides clinicians with a “new first-in-class therapeutic option that demonstrated faster healing in the more difficult-to-treat GERD...
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
News from the FDA/CDC
FDA approves abatacept for pediatric patients with psoriatic arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.
News from the FDA/CDC
FDA warns of hidden ingredients in arthritis, pain products
“I don’t know if this was intentional, but it seems suspicious that a product marketed to reduce joint pain and inflammation contains prescription...
News from the FDA/CDC
FDA approves subcutaneous infliximab for IBD
The new formulation was approved based on phase 3 pivotal trials that evaluated the safety and efficacy of infliximab-dyyb as maintenance therapy...